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Background: Airway inﬂammation, mediated in part by LTB4, contributes to lung destruction in patients with cystic ﬁbrosis (CF). LTB4-receptor
inhibition may reduce airway inﬂammation. We report the results of a randomized, double-blind, placebo-controlled study of the efﬁcacy and
safety of the leukotriene B4 (LTB4)-receptor antagonist BIIL 284 BS in CF patients.
Methods: CF patients aged≥6 years with mild to moderate lung disease were randomized to oral BIIL 284 BS or placebo once daily for 24 weeks.
Co-primary endpoints were change in FEV1 and incidence of pulmonary exacerbation.
Results: After 420 (155 children, 265 adults) of the planned 600 patients were randomized, the trial was terminated after a planned interim analysis
revealed a signiﬁcant increase in pulmonary related serious adverse events (SAEs) in adults receiving BIIL 284 BS. Final analysis revealed SAEs
in 36.1% of adults receiving BIIL 284 BS vs. 21.2% receiving placebo (p = 0.007), and in 29.6% of children receiving BIIL 284 BS vs. 22.9%
receiving placebo (p = 0.348). In adults, the incidence of protocol-deﬁned pulmonary exacerbation was greater in those receiving BIIL 284 BS
than in those receiving placebo (33.1% vs. 18.2% respectively; p = 0.005). In children, the incidence of protocol-deﬁned pulmonary exacerbation
was 19.8% in the BIIL 284 BS arm, and 25.7% in the placebo arm (p = 0.38).
Conclusions:While the cause of increased SAEs and exacerbations due to BIIL 284 BS is unknown, the outcome of this trial provides a cautionary
tale for the administration of potent anti-inﬂammatory compounds to individuals with chronic infections, as the potential to signiﬁcantly suppress
the inﬂammatory response may increase the risk of infection-related adverse events.
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In the cystic fibrosis (CF) lung, persistent infection, particularly
by Pseudomonas aeruginosa, drives excessive and persistent
polymorphonuclear neutrophil (PMN) infiltration, leading to
irreversible lung destruction and early death [1–3]. Recogni-
tion that the products of chronic inflammation are harmful to
the CF lung has resulted in strategies to reduce lung infection
[4] and the damage associated with chronic inflammation [5,6].
Several approaches have been studied in an attempt to
limit inflammation-mediated lung damage in patients with CF
[7]. To date, only high-dose ibuprofen, with a broad-based
anti-inflammatory mechanism of action, has been shown to be
effective [8–10], but this therapy has not been widely adopted by
CF clinicians [11]. An alternative approach to reducing chronic
inflammation is to use a more targeted anti-inflammatory
approach directed at known neutrophil chemoattractants in the
CF lung.
LTB4, produced by macrophages and PMNs in response to
various stimuli, including P. aeruginosa [12], is a potent
chemoattractant for and activator of PMNs [13], and along
with IL-8 is considered to play a significant role in the
recruitment of PMNs into CF airways [7]. Thus, inhibiting the
action of LTB4 using an LTB4 receptor antagonist may be
beneficial in the treatment of CF lung disease. There is strong
preclinical evidence to support the potential for clinical
efficacy of LTB4 receptor antagonists in CF including: high
levels of LTB4 in CF sputum and bronchoalveolar lavage fluid
[14,15], correlation between levels of LTB4 in the CF airway and
reductions in pulmonary function [16], and preliminary evidence
in CF patients of clinical efficacy with eicosanoid modulators
such as eicosapentaenoic acid (EPA) [17].
BIIL 284 BS is under development as an LTB4 receptor
antagonist for treating inflammation for a variety of medical
conditions. BIIL 284 BS is a prodrug that is converted in vivo
to active glucuronidated metabolites BIIL 260 and BIIL 315,
both of which have been reported to have high affinities to the
LTB4 receptor on isolated human neutrophil cell membranes
[18]. BIIL 284 BS has been shown to significantly inhibit
LTB4-induced mouse ear inflammation and monkey neutropenia
[18]. Following satisfactory results from two phase Ib trials
evaluating the safety, tolerability and pharmacokinetics of up
to 15 days of treatment with BIIL 284 BS in subjects with CF
[19,20], we conducted a 24 week multi-center, multi-national,
randomized, double-blind, placebo-controlled phase II clinical
trial (Boehringer Ingelheim 543.45) of the safety and efficacy of
BIIL 284 BS in patients with CF [21].2. Methods
This randomized double blind, placebo controlled trial was
conducted during the years 2003 to 2004 at 61 sites in 8 countries
(Belgium, Canada, France, Germany, The Netherlands, Sweden,
the United Kingdom, and the United States) in compliance with
the Declaration of Helsinki. Institutional review boards approved
the study for each site and all patients or their guardians providedwritten informed consent before any study procedures were
performed.
To be enrolled in the study, males and females ≥6 years of
age had to have a documented CF diagnosis, have a body
weight of ≥20 kg, were able to reproducibly perform
spirometry [22], and have forced expiratory volume in 1 s
(FEV1) ranging from 25% to 85% of their predicted value based
on age, sex, and height. In addition, adults (≥18 years of age)
with FEV1 N 85% predicted and current P. aeruginosa infection
were also eligible. FEV1 % predicted was calculated using the
reference equations of Wang et al. [23] for subjects≤18 years of
age and of Knudson et al. [24] for older subjects. In addition,
subjects were required to have been clinically stable (no evidence
of acute symptoms of upper or lower respiratory tract infection)
and not have received intravenous (IV), oral or inhaled antibiotics
or oral corticosteroids for treatment of a pulmonary exacerbation
within the 4 weeks preceding screening. Finally, subjects were
required to have an FEV1 within 10% of their screening FEV1 at
Day 0 and to agree to continue taking any chronic medications
they were currently receiving for the duration of the study.
Individuals were excluded from study participation if they had
persistent Burkholderia cepacia complex lung infection or were
treated chronically with oral corticosteroids or high-dose
ibuprofen to control lung inflammation.
After screening, subjects were randomized to each treatment
within each age group and study site in a ratio of 1:1 for 75 mg
active drug or placebo in pediatric subjects (6 to 17 years of age)
and in a ratio of 1:1:2 for 75 mg active drug, 150 mg active drug,
or placebo in adults (≥18 years), respectively. Treatment was
initiated at Day 0 (baseline) and subjects were monitored every
28 days until end of treatment (Day 168; 24 weeks). A follow-up
visit was scheduled 28 days after end of treatment (Day 196). Trial
medication was dispensed at each study visit and unused tablets
were collected before new medication was dispensed to assess
compliance.
Primary efficacy endpoints were change in FEV1 % predicted
from baseline and the proportion of subjects experiencing a
pulmonary exacerbation during the treatment period using the
Fuchs criteria [25]. Symptom changes associated with the Fuchs
criteria were captured via the Respiratory and Systemic
Symptoms Questionnaire (RSSQ) at each study visit [26].
The Fuchs criteria include treatment with intravenous anti-
biotics to meet the definition of a pulmonary exacerbation.
Secondary efficacy endpoints included change in forced vital
capacity (FVC) % predicted from baseline, time to pulmonary
exacerbation, proportion of patients receiving IV antibiotics,
time to IV antibiotic use, proportion of patients hospitalized,
and time to hospitalization. Adverse event monitoring was
assessed at each visit. Blood and urine sampling was also
included to assess for safety, and included complete blood counts
with differential among other laboratory tests. Oversight of the
trial was performed by the Cystic Fibrosis Foundation Data
Safety Monitoring Board (DSMB); a Data Monitoring Committee
(DMC), which was a subcommittee of the DSMB, served as the
review committee for the trial. The DMC consisted of 3 physicians
experienced in treating CF and a biostatistician. Safety data was
monitored by the DMC members on a continual basis throughout
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enrollment rates, the first DMC review was planned to take place
when 50% of the subjects had been randomized; if 50% enrollment
had not been achieved by 6 months of trial initiation, a review of
existing data was to be performed by the DMC at that time. Further
DMC reviews were to take place at regular intervals thereafter until
completion of the study (i.e. Last Patient Out). In addition to the
regularly scheduled reviews, there was also provision for ad hoc
reviews, if deemed necessary by the DMC or by the sponsor. The
DMC could recommend early termination of the study for reasons
of patient safety based on the interim review of this safety data.
The DMC reviews were focused on safety, with no formal
analysis of efficacy or futility of the primary endpoints. A
comprehensive, unblinded interim safety report was generated
for all members of the DMC to review. Adverse events were
tabulated by body system, intensity, seriousness and their
relationship to the study drug. Abnormal changes in laboratory
values were summarized. All available pulmonary function data
was summarized for the DMC review for the purpose of evaluating
the safety of BIIL 284 BS. The report was accompanied by listings
of adverse events and other safety data by subject. SAEs were
monitored by the DMC in real time throughout the trial. SAEs
were required to be reported by the Investigator to the sponsor
within 24 h of learning of the event. The sponsor then sent the SAE
report via fax to the DMC Chair.
A sample size of 600 patients was planned (300 each in the
pediatric and adult group) in order to provide N90% power to
detect a difference of a 3% predicted change from baseline in
FEV1 between placebo and active treatment assuming a
standard deviation of 11% predicted in each treatment group
and a two-sided level α = 0.05 test. This sample size was
also determined to provide 80% power to detect a difference
in exacerbation incidence between the two treatment arms
assuming a 30% exacerbation incidence in the placebo group
and a 20% incidence in the BIIL 284 BS group by chi-squared
test (α = 0.05). Proportions were compared using a two-sided
chi-squared test, and Kaplan–Meier survival curves and the
log-rank test were used for comparing time to pulmonary
exacerbation. Independent t-test was used to compare change
from baseline in spirometry measures and other clinical and
laboratory endpoints. Because of the potential bias incurred
by early termination of the study on estimation and testing,
p-values are reported for descriptive purposes.
3. Results
The first subject enrolled in the trial on May 20, 2003. The
first formal DMC review took place on October 29, 2003;
the DMC recommended to “proceed with study conduct”. A
second formal DMC review took place on February 18, 2004;
the DMC recommended again to “proceed with study conduct”.
Before the next scheduled formal DMC review, additional data
was requested based on the real-time ongoing reviews of SAEs.
After reviewing this data, the DMC requested a meeting with
the sponsor to discuss a potential safety issue. Because the data
being discussed were unblinded, only two internal sponsor
personnel were involved: a statistician independent from thetrial and the project leader. Termination of the trial was re-
commended by the DMC on May 13, 2004 and the lead
monitor was notified. Investigators, site staff and local monitors
were notified on May 14, 2004 and the trial was terminated. All
subjects were contacted immediately and instructed to discon-
tinue their study medication and return to their study site as
soon as possible for a final evaluation visit.
Of 579 eligible individuals screened, 420 were enrolled in
the trial. The planned target enrollment of 600 was not achieved
due to early termination of the trial; a significant proportion of
subjects were classified as screen failures as a direct consequence
of the early trial termination. A majority of randomized subjects
(258; 61.4%) were discontinued from the study, with 223 dis-
continuations due to safety concerns by the DMC and the sponsor
related to BIIL 284 BS. Other reasons for discontinuation were
adverse events (23), withdrawal of consent (9) and non-compli-
ance (3). The remaining 162 subjects (38.6%) completed the
entire 24 weeks of treatment (Fig. 1). Baseline subject character-
istics, including mean age, FEV1 % predicted, weight, and lung
infection status were well balanced between the pediatric and
adult treatment arms (Table 1). Pediatric subjects received BIIL
284 BS for a median of 102 days versus 114 days for those
receiving placebo. Adults received BIIL 284 BS (pooled groups)
for a median of 149 days versus 151 days for those receiving
placebo. Study drug compliance ranged between 92 and 98% for
each study arm.
The trial was terminated early due to disproportionate incidence
of respiratory serious adverse events (SAEs) observed among adult
subjects receiving BIIL 284 BS compared to those receiving
placebo. These SAEs were characterized by increased presentation
of respiratory signs and/or symptoms associated with pulmonary
exacerbation and resulted in admission to a hospital and/or
administration of IV antibiotics. At the time of the DMC analysis,
33 adults (29.7%) who had received either of the 2 doses of BIIL
284 BS had experienced an SAE versus only 12 (11.8%) of those
receiving placebo (p = 0.001), and 12 adults (10.8%) receiving
BIIL 284 BS had withdrawn from the study versus only 3 (2.9%)
receiving placebo (p = 0.031). A similar (but not statistically
significant) trend was observed in the pediatric population, with 12
pediatric subjects (19.7%) receiving BIIL 284 BS experiencing an
SAE versus 7 (11.5%) that had received placebo (p = 0.318).
Incidences of AE, SAE, and respiratory SAE in the final dataset
were similar to those observed in the interim safety analysis
(Table 2). In the pooled adult BIIL 284 BS arm, 48 of 133 (36.1%)
experienced an SAE vs. 28 of 132 (21.2%) in the placebo arm
(p = 0.007). In the pediatric BIIL 284 BS arm, 24 of 81 (29.6%)
experienced at least one SAE vs. 22.9% (17/74) in the placebo arm
(p = 0.348). The majority of all SAEs, 143/191 (74.9%), were
coded as respiratory in nature.
Treatment assignment for subjects with SAEs was con-
firmed by measuring plasma samples for BIIL 315 ZW. Plasma
concentrations of subjects with SAEs were in the expected
concentration range, and were similar to the results obtained in
earlier pharmacokinetic studies of BIIL 284 BS in adults and
children with CF [19]. The median plasma concentrations in the
time interval from 2 to 4 h after drug administration for the
150 mg BIIL 284 BS adult early withdrawal group with SAEs
Assessed for eligibility N=579
Failed Screening Criteria N=159
Discontinued : 44
Study Terminated: 41 
AE: 2
Non Compliant: 0
Consent Withdrawal: 1
Discontinued : 56 
Study Terminated: 51
AE: 2
Non Compliant: 1
Consent Withdrawal: 2
Discontinued : 79 
Study Terminated: 72
AE: 2
Non Compliant: 2
Consent Withdrawal: 3
Discontinued: 40 
Study Terminated: 28
AE: 10
Non Compliant: 0
Consent Withdrawal: 2
Completed 24 weeks 
therapy: 30 
Pediatric Subjects (over 6 but under 18 years) Adult Subjects (over 18 years)
Discontinued: 39
Study Terminated: 31
AE: 7
Non Compliant: 0
Consent Withdrawal: 1
Completed 24 weeks 
therapy: 25 
Completed 24 weeks 
therapy: 53 
Completed 24 weeks 
therapy: 26 
Completed 24 weeks 
therapy: 28 
Placebo : 74 BIIL 75 mg : 81 Placebo : 132 BIIL 150 mg : 67BIIL 75 mg : 66
Randomized N=420
Fig. 1. Subject disposition, consort diagram.
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with SAEs, were 45.2 ng/mL (N = 15) and 18.3 ng/mL (N = 12)
respectively. Prior to study termination, 103 (24.5%) treated
subjects had experienced a protocol-defined pulmonary exacerba-
tion. The incidence of exacerbation was significantly higher in
adult subjects receiving BIIL 284 BS than those receiving placebo
(33.12% versus 18.2%, p = 0.005). Similar numbers of pediatric
subjects were treated for a pulmonary exacerbation in the BIIL
284 BS and placebo groups (16/81, 19.8%, and 19/74, 25.7%,
respectively; p = 0.38). The Kaplan–Meier curves (Fig. 2) forTable 1
Subject demographics and baseline characteristics.
Characteristic Ped placebo
(N = 74)
Ped 75 mg
(N = 81)
Age, mean yr (range) 13.5 (6–18) 12.7 (6–17)
Male, n (%) 41 (55.0) 42 (51.9)
Caucasian, n (%) 72 (97.3) 79 (97.5)
CFTR genotype, n (%)
Homozygous ΔF508 42 (57.0) 47 (58.0)
Heterozygous ΔF508 22 (30.0) 19 (23.5)
Other/unknown 10 (14.0) 15 (18.5)
Sweat chloride, mean mEq/L (SD) 104 (19.5) 103.9 (17.3)
Weight, mean kg (SD) 45.0 (13.2) 42.8 (13.6)
BMI, mean kg/m2 (SD) 17.8 (2.5) 18.1 (3.0)
FEV1 % predicted, mean (SD) 73.1 (17.5) 71.8 (18.6)
FVC % predicted, mean (SD) 85.1 (13.7) 87.5 (17.3)
P. aeruginosa positive, n (%) 40 (54) 41 (50.6)
S. aureus positive, n (%) 36 (49) 39 (48.1)
Global ratings of health status
Investigator
Excellent 11 (15) 13 (16)
Good 51 (69) 57 (70.4)
Fair 12 (16) 11 (13.6)
Poor/missing 0 (0) 0 (0)
Patient
Excellent 13 (18) 11 (13.6)
Good 53 (72) 61 (75.3)
Fair 8 (11) 9 (11.1)
Poor/missing 0 (0) 0 (0)
Sweat chloride, genotype, and microbiology culture were ascertained at screening v
Age, weight, BMI, spirometry, and global ratings of health status were ascertainedtime to pulmonary exacerbation show statistically significant
differences in curves between treatment groups in adults
(p-value = 0.0023), but not across the treatment groups in
pediatric subjects.
Early study termination prevented the analyses of clinical
efficacy endpoints as planned in the protocol. However, descriptive
summary statistics of efficacy endpoints in which the data were
pooled for subjects in both adult dosing groups of BIIL 284 BS
suggest a trend towards poorer average lung function (FEV1 %
predicted) in subjects receiving BIIL 284 BS than in thoseAdult placebo
(N = 132)
Adult 75 mg
(N = 66)
Adult 150 mg
(N = 67)
30.8 (17–64) 28.8 (18–53) 30.5 (18–60)
68 (52.0) 36 (54.5) 38 (57.0)
124 (93.9) 62 (93.9) 64 (95.5)
51 (39.0) 26 (39.4) 26 (39.0)
54 (41.0) 28 (42.4) 27 (40.0)
27 (20.0) 12 (18.2) 14 (21.0)
101.5 (19.7) 103.6 (24.4) 102.3 (20.9)
62.4 (12.0) 60.8 (11.6) 63.7 (12.1)
21.8 (3.3) 21.4 (2.9) 22.1 (3.0)
56.3 (15.4) 53.0 (15.4) 58.1 (16.4)
78.9 (14.6) 74.8 (16.3) 80.1 (18.1)
85 (64) 42 (63.6) 38 (57)
43 (33) 14 (21.2) 19 (28)
21 (16) 7 (10.6) 10 (15)
89 (67) 46 (69.7) 48 (72)
22 (17) 13 (19.7) 8 (12)
0 (0) 0 (0) 1 (1.5)
11 (8) 6 (9.1) 8 (12)
92 (70) 55 (83.3) 51 (76)
28 (21) 5 (7.6) 7 (10.5)
1 (0.8) 0 (0) 1 (1.5)
isit.
at baseline visit.
Table 2
Summary of adverse events.
Pediatric placebo
(N = 74)
Pediatric 75 mg
(N = 81)
Adult placebo
(N = 132)
Adult 75 mg
(N = 66)
Adult 150 mg
(N = 67)
Adult pooled
(N = 133)
AEs
Total number 296 322 676 330 344 674
Subjects with ≥1, n (%) 67 (90.5) 72 (88.9) 109 (82.6) 61 (92.4) 60 (89.6) 121 (90.9)
Average number per subject 4.42 4.47 6.20 5.41 5.73 5.57
AE rate per wk of follow-up 0.25 0.26 0.32 0.32 0.43 0.38
SAEs
Total number 27 47 38 47 32 79
Subjects with ≥1, n (%) 17 (22.9) 24 (29.6) 28 (21.2) 27 (40.9) 21 (31.3) 48 (36.1)
Average number per subject 1.59 1.96 1.36 1.74 1.52 1.65
SAE rate per wk of follow-up 0.10 0.13 0.08 0.11 0.08 0.10
Respiratory SAEs
Total number 22 35 30 33 23 56
Subjects with ≥1, n (%) 17 (22.9) 22 (27.2) 22 (16.7) 24 (36.4) 17 (25.4) 41 (30.8)
Average number per subject 1.29 1.59 1.36 1.38 1.35 1.37
Rate per wk of follow-up 0.09 0.12 0.08 0.11 0.08 0.10
Treatment emergent AEs and SAEs: occur after the initiation of the first dose.
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increased over the study period for adults receiving BIIL 284 BS,
while they were reduced slightly for adults receiving placebo,
with significant differences between groups observed at Days 28,
84, and 140, but not at Day 168 (Table 3). In contrast, average
peripheral PMN count differences were significant for pediatric
subjects only at Day 28. Data for peripheral lymphocyte and
monocyte counts is included in the on-line supplement. Overall,
height, weight, and body mass index (BMI) did not significantly
change over the study period, and there was no effect of treatment
group on change from baseline for these measures.
4. Discussion
Several clinical and experimental lines of evidence have
suggested that LTB4 plays a key role in the pathophysiology of0 28 56 84 112 140 168 196 224
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Fig. 2. Time to protocol-defined pulmonary exacerbation.CF and other inflammatory diseases by promoting neutrophil
adherence, aggregation, migration, degranulation, and superoxide
release [27–33]. Thus, inhibition of LTB4 via antagonism of the
LTB4 receptor was anticipated to provide some protective benefit
to the CF lung with respect to inflammation and inflammatory
damage. The early termination of this trial as a result of increased
respiratory symptoms requiring IV antibiotics and hospitalization
in adults receiving the LTB4-receptor antagonist BIIL 284 BS,
combined with evidence of decreased pulmonary function and
increased circulating PMN levels in subjects receiving BIIL 284
BS, suggests that antagonism of the LTB4 receptor may have
resulted in acute pulmonary exacerbations possibly associated with
increased inflammation. Although significant safety concerns were
evident only in adult subjects, the DMC included pediatric subjects
in its recommendation for study termination because 1) the relative
risk for drug-related SAE in the pediatric cohort was quantitativelyTime (days)
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Fig. 3. Change in lung function.
Table 3
Change from baseline of peripheral neutrophil count (PMN).
Treatment group
Placebo BIIL 75 mg BIIL 150 mg Difference (BIIL–placebo) a
Week N Mean (SD) N Mean (SD) N Mean (SD) Mean (95% CI) p-Value
Pediatric 74 80
PMN (109/L) 4 66 −0.3 (3.1) 71 0.7 (2.8) 1.0 (0.0–2.0) 0.049
Change from baseline b 12 45 −0.5 (2.5) 44 0.4 (2.8) 0.9 (−0.2–2.0) 0.124
20 35 −0.1 (2.6) 31 −0.1 (2.8) 0.0 (−1.4–1.3) 0.975
24 28 0.2 (3.0) 25 0.4 (2.6) 0.2 (−1.3–1.8) 0.762
Adult 131 65 64
PMN (109/L) 4 116 −0.7 (2.6) 55 0.8 (3.0) 57 0.8 (2.5) 1.5 (0.8–2.2) b .0001
Change from baseline c 12 81 −0.2 (2.6) 38 1.4 (2.9) 43 0.1 (3.1) 0.9 (0.0–1.8) 0.045
20 68 −0.2 (3.0) 31 2.0 (5.9) 37 0.8 (2.9) 1.6 (0.3–2.9) 0.019
24 52 −0.4 (3.6) 25 0.9 (2.6) 28 0.3 (2.6) 1.0 (−0.2–2.2) 0.117
a For adults, calculated using pooled data from BIIL 75 mg and BIIL 150 mg.
b Baseline: placebo = 6.1 (3.2); BIIL 75 mg = 5.7 (2.6).
c Baseline: placebo = 6.9 (3.2); BIIL 75 mg = 5.9 (2.4); BIIL 150 mg = 6.0 (2.5).
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lower power to detect statistically significance differences in the
pediatric cohort due to a lower level of recruitment, 3) there
were no biological bases to assume that children should have
a fundamentally different response to drug, 4) it was recognized
that the study would be underpowered to detect benefit without
participation of the adult cohorts, and 5) the early results of
change in FEV1 did not appear to be supporting a beneficial
effect of drug. The results from the final data presented here
support and confirm the decision to terminate the trial.
The mechanism by which antagonism of the LTB4 receptor
in subjects with CF might produce an increase in respiratory
symptoms and concurrent decrease in pulmonary function is not
clear. Many subjects in the study had chronic lung infection with
pathogenic bacteria such as P. aeruginosa and Staphylococcus
aureus. It may be that a substantial reduction in PMN activity at
the site of infection in the lung due to LTB4 receptor antagonism
actually increased bacterial proliferation in the lung and possibly
invasion into the parenchyma, which might explain why cir-
culating counts of PMN were observed to be significantly
elevated.
The therapeutic approach of reducing PMN-mediated inflam-
mation in the CF lung by targeting LTB4 was suggested by a
study using a rat model of chronic Pseudomonas infection [34].
In that study, ibuprofen inhibited LTB4 release from neutro-
phils and reduced neutrophils in the lung without worsening
Pseudomonas infection. Long-term clinical trials and clinical
practice suggest that the benefits of ibuprofen outweigh the
risks in patients with CF [8–10]. It is possible that the doses
of BIIL 284 BS chosen for this trial were higher than those
necessary to effectively reduce PMN-based inflammation
without allowing undesirable expansion of bacterial populations.
The efficacy and safety of BIIL 284 BS have been evaluated in
subjects with active rheumatoid arthritis in a 3-month multi-
center, randomized, double-blind, placebo-controlled trial [35,36].
A total of 342 subjects were randomized to receive 5 mg, 25 mgor 75 mg doses of BIIL 284 BS or placebo. The geometric mean
concentration of BIIL 315 ZW for samples taken 1 to 4 h post-
dose was 19.4 mg/mL after treatment with 75 mg BIIL 284 BS,
which is in the same range as the levels observed in the current
study. In the rheumatoid arthritis study, BIIL 284 BS was
determined to be safe and well tolerated. However, BIIL 284 BS
produced only modest improvements in disease activity.
This trial of BIIL 284 BS in children and adults with CF
highlights the value of incorporating an ongoing review of
the safety data by an external, independent DMC into the
study design. Also to be noted, the communication infrastructure
available to the sponsor allowed for a rapid response following the
DMC recommendation to terminate the study, both with regard to
the decision-making process of the sponsor (i.e. decision to comply
with the DMC recommendation) and the communication to the
Investigators to discontinue all subjects from treatment.
The safety concern raised in this trial of a leukotriene
receptor antagonist that targets a peptido-leukotriene (LTB4)
cannot be extrapolated to leukotriene receptor antagonists
that target cysteinyl leukotrienes (LTC4, LTD4, and LTE4). The
former contributes to neutrophilic inflammation in the lung,
while the latter, produced predominantly by eosinophils, mast
cells, and macrophages, contribute to non-neutrophilic pulmo-
nary inflammation [37]. The cysteinyl leukotriene receptor
antagonist, montelukast, is frequently used to treat asthma, and
has been used in patients with CF (particularly in those with
bronchial hyperreactivity) with some evidence for benefit
without apparent complications that would limit their use [37].
The outcome of this trial of BIIL 284 BS provides a cautionary
tale for the administration of potent anti-inflammatory compounds
to individuals with chronic infections, as the potential to signifi-
cantly suppress the inflammatory response may increase the risk of
infection-related adverse events. To mitigate risk in future trials
of anti-inflammatory compounds in patients with CF, frequent
monitoring for adverse events and perhaps including sputum
biomarkers of infection and inflammation should be considered.
154 M.W. Konstan et al. / Journal of Cystic Fibrosis 13 (2014) 148–155The inclusion of a robust data safety monitoring committee with
pre-defined safety and efficacy assessments, as was done in this
trial, is paramount.
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